ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Amarin Corporation Plc Sponsored ADR (AMRN) Report Updated: Apr 25, 2016 | Print This Page

Get more stock ratings by Louis Navellier

Amarin Corporation Plc Sponsored ADR (AMRN)

Rating: Hold Volatility: Moderate
Total Grade: C Industry: Biotechnology
Competitors:

Stock Analysis

Rating: Monthly View

A
B
C
D
F
April May June July August September October November December January February March

Rating: Weekly View

This Week: C down no change
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

Amarin Corporation Plc Sponsored ADR© quotemedia

Company Profile

Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States. The company’s lead product includes Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.